|
Clinical Trials
Diabetes: Low Blood Glucose Levels Do Not Explain Excess Deaths in ACCORD TrialDate:
06/09/2009
, Publication:
ADA
, Author:
American Diabetes Association
http://www.diabetes.org/for-media/pr-accord-trial.jsp
Heart Failure: Rolofylline Did Not Demonstrate Efficacy for Acute Heart Failure in Clinical TrialDate:
06/05/2009
, Publication:
PharmaLive
, Author:
BUSINESS WIRE
http://www.pharmalive.com/News/index.cfm?articleid=632025
Antibiotic: PolyMedix Initiates Dosing in Second Phase I Clinical Study of Novel Systemic Antibiotic CompoundDate:
06/05/2009
, Publication:
PharmaLive
, Author:
BUSINESS WIRE
http://www.pharmalive.com/News/Index.cfm?articleid=632013
Diabetes: Overall Cardiovascular Safety Of Rosiglitazone Confirmed In 5½-Year StudyDate:
06/05/2009
, Publication:
ADA
, Author:
American Diabetes Association
http://www.diabetes.org/for-media/pr-overall-cardiovascular-safety-of-rosiglita
Head-Neck Cancer: Genmab Announces Partial Clinical Hold on Zalutumumab StudiesDate:
06/04/2009
, Publication:
PharmaLive
, Author:
PharmaLive
http://www.pharmalive.com/News/index.cfm?articleid=631583
HIV: Positive Outcome Reached at 16 Weeks for Avexa's ATC Phase III TrialDate:
06/04/2009
, Publication:
PharmaLive
, Author:
BUSINESS WIRE
http://www.pharmalive.com/News/Index.cfm?articleid=631714
Osteoporosis: Halozyme Drops Osteoporosis Phase I ProgramDate:
06/04/2009
, Publication:
PharmaLive
, Author:
BUSINESS WIRE
http://pharmalive.com/news/index.cfm?articleID=631611&categoryid=9&newsletter=1
Melanoma: Genasense Combined with Temodar and Abraxane Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced MelanomaDate:
06/03/2009
, Publication:
PharmaLive
, Author:
BUSINESS WIRE
http://www.pharmalive.com/News/Index.cfm?articleid=631373
Osteoarthritis and Rheumatoid Arthritis: CombinatoRx Announces Positive Results for Aligned-Release SynaviveDate:
06/03/2009
, Publication:
PharmaLive
, Author:
BUSINESS WIRE
http://www.pharmalive.com/News/Index.cfm?articleid=631366
Migraine: Almotriptan (Axert/Almogran) Approved by the FDA for the Treatment of Migraine in AdolescentsDate:
06/03/2009
, Publication:
PharmaLive
, Author:
PharmaLive
http://pharmalive.com/news/index.cfm?articleID=631453&categoryid=9&newsletter=1
Previous
Page 1 of 15
Next >
Search returned 143 items.
|
Sponsored Links
Clinical Researchers, others from
subscriber lists and assoc's.
www.biotechmedia.com
Reach these Drug Developers
Via Email or Mail List Rentals
www.biotechmedia.com
This twice-monthly news magazine
reports on all phases of pharmacy
www.drugtopics.com
|